Clinical trials: Semaglutide, completed
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Chronic Weight Management
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
- Trial name
- NCT06972992
- Testing
- ASC47 +Semaglutide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity & Overweight
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug…
- Trial name
- NCT07216651
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Closed Loop Medicine
Healthy
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time.
- Trial name
- NCT06699329
- Testing
- Enlicitide Decanoate, Semaglutide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
- Trial name
- NCT01923181
- Testing
- semaglutide
- Where
- 103 sites in United States, Austria and 12 more
- Volunteers
- 632 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT06659679
- Testing
- New use of oral semaglutide, New initiation of sitagliptin
- Where
- United States
- Volunteers
- 26,126 people
- Sponsor
- Brigham and Women's Hospital
Obesity
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo).
- Trial name
- NCT04969939
- Testing
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
- Where
- 25 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
- Trial name
- PIONEER 1 (NCT02906930)
- Testing
- semaglutide
- Where
- 105 sites in United States, Algeria and 9 more
- Volunteers
- 703 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of HS-20094 in T2DM Participants
This is a randomized, placebo and active-control, multiple-dose, phase IIa trial. Patients were randomly assigned to receive HS-20094 (12 patients), placebo (3 patients), or active control drug Semaglutide injection (3 patients)…
- Trial name
- NCT06118008
- Testing
- HS-20094 5mg, HS-20094 10mg, HS-20094 15mg
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Overweight, Obesity
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 3 (NCT03611582)
- Testing
- Semaglutide
- Where
- 41 sites in United States
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT05230615)
- Testing
- Oral semaglutide
- Where
- 2 sites in Italy
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Chinese men when it is given at different doses together with a fixed dose of semaglutide.
- Trial name
- NCT05498610
- Testing
- NNC0480 0389, Semaglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
- Trial name
- NCT07850765
- Testing
- Semaglutide
- Where
- 6 sites in Israel, Mexico and 4 more
- Volunteers
- 1,260 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus
This real-world, comparative cohort study aims to evaluate the 12-month effectiveness of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2D), with a specific focus on sex-based differences in…
- Trial name
- NCT07056803
- Testing
- Oral semaglutide, subcutaneous semaglutide
- Where
- Italy
- Volunteers
- 212 people
- Sponsor
- University of Palermo
Overweight and Obesity
Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity
This clinical trial investigated the combined effects of Semaglutide and a fiber supplement (glucomannan, inulin, psyllium) on weight loss in adults with overweight or obesity.
- Trial name
- ESSENCE (NCT06215196)
- Testing
- Fiber Supplement Group
- Where
- Russia
- Volunteers
- 81 people
- Sponsor
- S.LAB (SOLOWAYS)
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
The aim of the study is to investigate the effect of the medicines, probenecid and ciclosporin on the concentrations of SNAC. SNAC is an ingredient of the semaglutide tablets.
- Trial name
- NCT03466567
- Testing
- Semaglutide, Probenecid, Ciclosporin
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric…
- Trial name
- NCT02773381
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months.
- Trial name
- NCT03648281
- Testing
- Semaglutide
- Where
- 30 sites in Denmark, Sweden
- Volunteers
- 333 people
- Sponsor
- Novo Nordisk A/S